Gong Xiangwei sold $488K of ATR

Gong Xiangwei (President, Asia) sold 4,200 shares of APTARGROUP, INC. (ATR) at $116.13 ($0.49M total) on 2026-05-26.

Original reporting
SEC EDGAR · Gong Xiangwei
Published May 27, 2026, 7:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 7:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATR
Neutral
medium confidence
Mentioned
$ATR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRNeutralLow
01

Why it matters

Because the disclosure contains only an officer’s sale details and no accompanying corporate catalyst, the market impact is likely sentiment-driven rather than fundamental.

02

Market read

Traders may briefly reassess sentiment around ATR due to insider selling, but the filing alone is unlikely to change valuation without additional news.

03

What to watch

No 10b5-1 plan is indicated; traders may overinterpret timing—compare with prior insider trades and total insider ownership trend.

Relevance 6/10Timing: Immediate (today’s filing) but event likely informationally weak.

Background

The article is an SEC Form 4 insider transaction disclosure (open-market sale) for AptarGroup, Inc. (ATR).

Company-level read

Ticker impact

$ATRNeutralMedium confidence
Context

SEC Form 4 shows ATR President, Asia Gong Xiangwei sold 4,200 shares for about $487,765 on 2026-05-26.

Expected impact

Likely limited/short-lived reaction; watch for follow-on insider activity or unusual volume.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan stated; however, it provides no new company-specific operational or financial information.

Market effects

No clear sector read-through from a single insider sale absent broader corporate news.

Minimal; transaction is company-specific and not tied to regional macro catalysts in the article.

Low; no international deal/regulatory/earnings linkage mentioned.

Counterpoint

The sale could be for diversification or personal liquidity rather than a negative view on ATR’s prospects.

Key entities

  • AptarGroup, Inc.

    ATR; officer Gong Xiangwei reported an open-market sale of 4,200 shares on 2026-05-26.

  • Gong Xiangwei

    President, Asia; sold $487,764.90 worth of ATR shares; holdings after sale: 10,774 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATRHighAI 8/10

Aptar Q3 2026 slides: broad growth, strong Pharma pipeline

AptarGroup (NYSE:ATR) reported Q3 2026 sales of $1.019B, up 6% YoY, with adjusted EPS of $1.52 beating estimates. Growth was seen across all segments, but margins were pressured. The Pharma segment grew 2% reported, 1% core, while Beauty grew 9% reported, 8% core, and Closures grew 11%. Management expects Q4 adjusted EPS of $1.39-$1.47, up 17% YoY.

$ATRMed

AptarGroup Inc (ATR) (Q3 2026) Earnings Call Highlights: Core Sales Grow 5% as Pharma

AptarGroup Inc (ATR) reported Q3 2026 core sales growth of 5% across all segments, with Pharma, Beauty, and Closures up 8%, 8%, and 11% respectively. Adjusted EPS was $1.52, down 6% YoY. Pharma growth was impacted by emergency medicine destocking, expected to affect full-year sales by $65M. Beauty and Closures margins declined due to operational challenges. CEO Gael Touya outlined plans for multi-year transformation in Beauty and reiterated long-term growth targets for Pharma.

$ATRMedAI 8/10

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup (ATR) reported Q3 earnings, highlighting growth in beauty, closures, and pharma sectors. Beauty core sales rose 8%, while closures saw 11% growth. Pharma developments include collaborations and acquisitions. The company recorded a $61.2M charge related to its Russian subsidiary. ATR forecasted Q4 adjusted EPS of $1.39-$1.47, up 17% YoY. Full-year capex is expected at $260M-$280M. Virginie Maes will lead Aptar Pharma starting January 1.